The Oxford covid-19 vaccine candidate has produced promising early trial results

The news: A covid-19 vaccine candidate being developed by Oxford University and AstraZeneca has is safe, and provoked a strong immune response in its first clinical trials. Participants’ systems producing both antibodies and T-cells and only experienced relatively mild side effects. The results were described today in a paper in The Lancet. The study: The…

The Oxford covid-19 vaccine candidate has produced promising early trial results

The news: A covid-19 vaccine candidate being developed by Oxford University and AstraZeneca has is safe, and provoked a strong immune response in its first clinical trials. Participants’ systems producing both antibodies and T-cells and only experienced relatively mild side effects. The results were described today in a paper in The Lancet.

The study: The trial consisted of 1,077 healthy adults who either received the experimental vaccine, called ChAdOx1 nCoV-19, or a meningitis vaccine. Antibody responses peaked by day 28 and remained high until day 56 of the trial, which was the last day of testing. A sub-group of 10 participants who received a second dose produced even stronger antibody responses. The covid-19 vaccine also resulted in “marked increases” in T-cell responses as early as day 7, which were still present when researchers tested the participants again on the final day. T-cells are a type of white blood cell that recognize and attack an invading virus. Provoking a strong T-cell response could be important as there is growing evidence it might be crucial to producing any form of lasting immunity to SARS-CoV-2.

The vaccine caused minor side effects in 70% of recipients, most commonly fatigue and headache, but these were treatable with paracetamol, the authors said.

Also in China: Initial results for a second vaccine candidate being developed by CanSino Biologics in Wuhan, China were also reported in The Lancet today. The trial of 508 healthy adults found that more than 96% of participants developed antibodies, while over 90% had T-cell responses.

What’s next: While these results are promising, it’s still too early to know if either vaccine offers sufficient protection from infection—or how long any such protection might last. Further trials of the Oxford vaccine involving more than 10,000 people are already underway in the UK, while 30,000 people are being recruited in the US, plus 5,000 in Brazil and 2,000 in South Africa. The UK has already ordered 100 million doses of the vaccine.